blue cross blue shield glp 1 of Massachusetts will stop covering popular drugs for weight loss. Here's why Blue Cross Blue Shield plans

Med Lett Drugs Ther (2022) 64(1654):1057

These changes were accompanied by preservation of structural proteins including aggrecan and collagen II, along with reduced caspase-3mediated apoptosis, suggesting a coordinated reduction in glycation-driven cellular stress and tissue degradation

Innovations such as oral semaglutide and dual agonists (e.g., tirzepatide) have further enhanced therapeutic reach (Aroda et al., 2019

Encapsulation of exenatide in poly-(D,L-lactide-co-glycolide) microspheres produced an investigational long-acting once-weekly formulation for type 2 diabetes

A: Current trial data suggests orforglipron may produce around 9% to 10% body weight reduction in some populations, while injectable semaglutide has shown higher average weight-loss outcomes in longer trials